CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 129 enrolled
Drug / intervention
RhinAer ARC Stylusdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04614324
NCT04614324N/ACompleted
CompareCT.gov

A Prospective, Open Label, Multi-Center Study Using the RhinAer Procedure for Treatment of Subjects Suffering With Chronic Rhinitis

Aerin Medical·interventional·Posted Nov 4, 2020·Updated Aug 28, 2025

In Brief

A clinical study evaluating RhinAer ARC Stylus for Chronic Rhinitis. Completed, enrolled 129 participants across 15 sites in 2 countries.

Detailed Summary

Post-market study to continue to evaluate the effectiveness of the RhinAer ARC Stylus for chronic rhinitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Rhinitis
CountriesGermany, United States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 4, 2020
Enrollment StartOct 5, 2020
Primary CompletionJun 30, 2021
Study CompletionDec 20, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.7 years ago

Interventions

RhinAer ARC Stylusdevice

The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).